A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Clinical trial NCT06024239 · COMPLETED

Trial details

NCT number: NCT06024239
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Volunteers Generalized Anxiety Disorder (GAD)Bipolar Disorder (BPD)

Start date: 2023-08-31
Primary completion: 2025-03-04
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.